Innate Pharma S.A. financial statements, including revenue, expenses, profit, and loss
The total revenue of IPHA for the last semiannual is 8.96 M USD, and it's 49.95% lower compared to the previous semiannual. The net income of H1 24 is -26.77 M USD.